1. Pink Sheet

How Did US FDA Get Octapharma To Drop Its Suit?

 
• By Brenda Sandburg

Company sought court order to vacate agency’s approval of the fibrinogen products of three blood centers, saying they were wrongly exempt from clinical trials required for Octapharma’s Fibryga.

Path forward
US FDA and Octapharma find 'administrative path forward' to resolve litigation • Source: Shutterstock

Seventeen months after Octapharma USA Inc sued the US Food and Drug Administration to compel the agency to rescind approval of plasma-derived fibrinogen products sponsored by three blood centers, the parties agreed to dismissal of the complaint.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership